|Healthcare Review: BioScrip Inc, Medivation Inc, Array Biopharma Inc, Celldex Therapeutics, RadNet Inc.|
|By Staff and Wire Reports|
|Friday, 09 May 2014 12:35|
Medivation Inc ($MDVN)’s shares jumped 7.72% to $64.63 after the company yesterday reported Q1 EPS of ($0.18), $0.09 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $95.7 million versus the consensus estimate of $94.64 million.
Array Biopharma Inc (ARRY)’s shares soared 7.81% to $3.93. Recently, the company announced that as part of its continued evolution toward late-stage development and commercialization, Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer of Mirati Therapeutics, joined the company's board of directors, effective April 25, 2014.
Celldex Therapeutics, Inc. ($CLDX)’s shares added 9.08% to $12.10. Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
RadNet Inc. (NASDAQ:RDNT)’s shares gained 14.10% to $6.07. The company reported Q1 EPS of ($0.03), $0.03 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $168.9 million versus the consensus estimate of $173.53 million.